Skip to main content
Equibles

BLRX · BioLineRx Ltd. · Metrics

Track BLRX — free

Use BLRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BLRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.21 +0.23 (+11.84%) At close · Oct 20
Rebalance outlook locked
Market Cap
$11.02M
Shares
4.98M
Volume · Oct 20 3057 Avg daily vol (3M) 17.32K

BLRX metrics

61 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.21
Market cap
$11.02M

Price action

20 metrics
Price change (1W)
+2.1%
Price change (30D)
-10.7%
Price change (3M)
-24.2%
Price change (6M)
-4.5%
Price change (YTD)
-20.1%
Price change (1Y)
-40.8%
Trailing year
Price change (5Y)
—
52-week high
$3.78
52-week low
$1.98
Change from 52-week high
-41.4%
Change from 52-week low
+11.8%
Annualized volatility
60.5%
Annualized volatility (3M)
55.8%
Beta
0.7
RSI (14D)
44.5
Price vs SMA 50
-11.8%
Price vs SMA 200
-20.2%
Avg volume (3M)
17,316
Relative volume
0.2
Average dollar volume
$44,420

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.98M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
7.9×
reciprocal yield 12.6%
P / book
0.8
reciprocal yield 124.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-92.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-31

Profitability

9 metrics
Gross margin
80.0%
Operating margin
-874.3%
Trailing 12 months
Net margin
-728.4%
Gross profit (TTM)
$1.11M
Operating profit (TTM)
−$12.17M
Net income (TTM)
−$10.14M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$292.06

Growth

11 metrics
Revenue growth YoY
-3.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+16.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-73.6%
Return on assets
-30.3%
Debt / equity
—
Current ratio
1.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.0
Interest coverage
-11.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$4.63M
Total assets
$33.48M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.80M
Capital expenditures (TTM)
—
R&D (TTM)
$9.62M
SG&A (TTM)
—
Stock compensation (TTM)
$306,000
R&D / revenue
690.7%
Stock compensation / revenue
22.0%

Ownership (13F)

9 metrics
13F filers
14
13F filer change QoQ
0
Institutional ownership
2.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+273.8%
Holder tenure
2.3
Price vs estimated holder cost
+7.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 11.1 days to cover
Days to cover
11.1d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1498403 CUSIP 09071M304 Visit website Investor relations